ArticleBlood advances2020
End-of-life care quality outcomes among Medicare beneficiaries with hematologic malignancies.
Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Quality End-of-Life Cancer Care: An Unfulfilled but Achievable Imperative.Current oncology reports · 2025Pooled it
- Hospice Enrollments From The Emergency Department Feature Short Admissions And High-Acuity Hospice Care.Health affairs (Project Hope) · 2026Article
- Article
- Palliative care involvement and intensity of end-of-life care among adolescents and young adults with cancer: a population-based study.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025Article
- Portable Medical Orders and Inpatient Cost at End of Life in Acute Myeloid Leukemia and Myelodysplastic Syndromes.JCO oncology practice · 2025Article
- Receipt of specialized palliative care and health care utilization at the end of life in hematological cancer patients - the Stockholm experience.Acta oncologica (Stockholm, Sweden) · 2025Observational
- Contemporary Patterns of End-of-Life Care Among Medicare Beneficiaries With Advanced Cancer.JAMA health forum · 2025Article
- End-of-life care in hematological malignancies - a nationwide comparative study on the Swedish Register of Palliative Care.PloS one · 2025Observational
- Challenges in hospice and end-of-life care in the transfusion-dependent patient.Hematology. American Society of Hematology. Education Program · 2024Review
- Updates on strategies to integrate palliative care in hematologic malignancy.Hematology. American Society of Hematology. Education Program · 2024Article
- Utilization and quality of palliative care in patients with hematological and solid cancers: a population-based study.Journal of cancer research and clinical oncology · 2024Article
- Article
- Perspectives on Transfusions for Hospice Patients With Blood Cancers: A Survey of Hospice Providers.Journal of pain and symptom management · 2024Article
- Frequency of anticancer drug use at the end of life: a scoping review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Silent Conversations: Goals of Care and End-of-Life Quality in Relapsed High-Risk Leukemia.Journal of the advanced practitioner in oncology · 2023Article
- Functional status and therapy for older adults with diffuse large B-cell lymphoma in nursing homes: A population-based study.Journal of the American Geriatrics Society · 2023Article
- Advancing Palliative Care Integration in Hematology: Building Upon Existing Evidence.Current treatment options in oncology · 2023Review
- Differential Impact of a Multicomponent Goals-of-Care Program in Patients with Hematologic and Solid Malignancies.Cancers · 2023Article
- End-of-Life Care of Acute Myeloid Leukemia Compared with Aggressive lymphoma in Patients Who Are Eligible for Intensive Chemotherapy: An Observational Study in a Japanese Community Hospital.Palliative medicine reports · 2023Article
- Global Risk Indicator and Therapy for Older Patients With Diffuse Large B-Cell Lymphoma: A Population-Based Study.JCO oncology practice · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Patients with hematologic malignancies are thought to receive more aggressive end-of-life (EOL) care and have suboptimal hospice use compared with patients with solid tumors, but descriptions of EOL outcomes from comprehensive cohorts have been lacking. We used the population-based Surveillance, Epidemiology, and End Results-Medicare dataset to describe hospice use and indicators of aggressive EOL care among Medicare beneficiaries who died of hematologic malignancies in 2008-2015. Overall, 56.5% of decedents used hospice services for median 9 days (interquartile range, 3-27), 33.0% died in an acute hospital setting, 36.8% had an intensive care unit (ICU) admission in the last 30 days of life, and 13.3% received chemotherapy within the last 14 days of life. Hospice use was associated with 96% lower probability of inpatient death (adjusted risk ratio [aRR], 0.038; 95% confidence interval [CI], 0.035-0.042), 44% lower probability of an ICU stay in the last 30 days of life (aRR, 0.56; 95% CI, 0.54-0.57), and 62% decrease in chemotherapy use in the last 14 days of life (aRR, 0.38; 95% CI, 0.35-0.41). Hospice enrollees spent on average 41% fewer days as inpatient during the last month of life (adjusted means ratio, 0.59; 95% CI, 0.57-0.60) and had 38% lower mean Medicare spending in the last month of life (adjusted means ratio, 0.62; 95% CI, 0.61-0.64). These associations were consistent across histologic subgroups. In conclusion, EOL care quality outcomes and hospice enrollment were suboptimal among older decedents with hematologic cancers, but hospice use was associated with a consistent decrease in aggressive care at EOL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.